![]() |
市场调查报告书
商品编码
1906696
2021-2031年锝-99m市场规模及预测、全球及区域份额、趋势和成长机会分析报告涵盖范围:按应用、最终用户和地理划分Technetium-99m Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, End User and Geography |
||||||
在美国,锝-99m市场正稳步扩张,这主要得益于先进的医疗基础设施、患者意识的提高以及核医学影像技术的广泛应用。医院和诊断中心正增加对SPECT/CT等混合影像系统的投资,以提高诊断准确性和工作流程效率。心血管疾病、癌症和骨骼疾病的日益普遍,推动了心臟病学、肿瘤学和骨骼扫描等领域对基于锝-99m影像技术的需求。包括碲化镉锌(CZT)侦测器和先进重建软体在内的技术创新,进一步提高了影像质量,缩短了扫描时间,并最大限度地减少了患者的辐射暴露。强大的钼-99/锝-99m发生器供应链确保了锝-99m放射性药物的稳定供应,从而支持其常规临床应用。此外,对用于肿瘤和神经成像的新型示踪剂的持续研究有望拓展其临床应用,进一步巩固锝-99m作为美国医疗保健市场首选诊断同位素的主导地位。
中东和非洲(MEA)的锝-99m(Tc-99m)市场正崛起为一个极具成长潜力的地区,这主要得益于医疗基础设施投资的增加、核子医学意识的提高以及慢性病患病率的上升。沙乌地阿拉伯、阿联酋、南非和埃及等国处于领先地位,其政府积极支持先进诊断技术的应用。医院和诊断中心正在扩展核医能力,引入SPECT/CT等混合影像系统,进而提高心血管、肿瘤、骨骼和其他器官特异性应用的诊断精度。
该地区心血管疾病、癌症和呼吸系统疾病负担日益加重,导致对基于Tc-99m的影像检查的需求不断增长。对医疗基础设施的投资,特别是对私人医院和专科诊断中心的投资,正在推动先进影像设备的安装。此外,与全球供应商和技术供应商的合作也帮助该地区的医疗机构获得最新的影像技术创新,包括碲锌镉(CZT)侦测器和先进的影像重建软体。
儘管面临设备成本高昂和训练有素的人员有限等挑战,但中东和非洲(MEA)市场正受益于政府推动医疗现代化的各项倡议,包括改善放射性药物的获取途径和加强监管支持。可靠的钼-99/锝-99m产生器的供应确保了稳定的供应,从而能够用于常规诊断。随着患者意识的提高、医疗投资的增加以及现代影像技术的普及,预计未来几年中东和非洲锝-99m市场将保持稳定持续成长。
The Technetium-99m Market size was US$ 4.54 billion in 2024 and is expected to reach US$ 6.03 billion by 2031. The Technetium-99m market size is estimated to register a CAGR of 4.2% during 2025-2031.
The U.S. Technetium-99m market is expanding steadily, driven by advanced healthcare infrastructure, high patient awareness, and widespread adoption of nuclear medicine imaging. Hospitals and diagnostic centers are increasingly investing in hybrid imaging systems such as SPECT/CT to enhance diagnostic accuracy and workflow efficiency. The growing prevalence of cardiovascular diseases, cancer, and bone disorders is fueling demand for Tc-99m-based imaging across cardiology, oncology, and bone scans. Technological innovations, including cadmium-zinc-telluride (CZT) detectors and advanced reconstruction software, are further improving image quality, reducing scan times, and minimizing radiation exposure for patients. Strong Mo-99/Tc-99m generator supply chains ensure consistent availability of Tc-99m radiopharmaceuticals, supporting routine clinical use. In addition, ongoing research into novel tracers for tumor and neurological imaging is expected to expand clinical applications, reinforcing Tc-99m's dominance as the preferred diagnostic isotope in the U.S. healthcare market.
The Middle East and Africa (MEA) Technetium-99m (Tc-99m) market is emerging as a region of significant growth potential, driven by increasing investment in healthcare infrastructure, rising awareness of nuclear medicine, and growing prevalence of chronic diseases. Countries such as Saudi Arabia, UAE, South Africa, and Egypt are at the forefront, with governments actively supporting the adoption of advanced diagnostic technologies. Hospitals and diagnostic centers are expanding nuclear medicine capabilities to include hybrid imaging systems like SPECT/CT, improving diagnostic precision for cardiovascular, oncology, bone, and other organ-specific applications.
The rising burden of cardiovascular diseases, cancer, and respiratory disorders in the region is increasing demand for Tc-99m-based imaging procedures. Investments in healthcare infrastructure, particularly in private hospitals and specialized diagnostic centers, are supporting the installation of advanced imaging equipment. Additionally, collaborations with global suppliers and technology providers are helping regional facilities access the latest imaging innovations, including CZT detectors and advanced image reconstruction software.
Despite certain challenges such as high equipment costs and limited trained personnel, the MEA market is benefiting from growing government initiatives promoting healthcare modernization, including improved access to radiopharmaceuticals and enhanced regulatory support. The availability of reliable Mo-99/Tc-99m generators ensures consistent supply, enabling routine diagnostic use. With increasing patient awareness, healthcare investments, and adoption of modern imaging technologies, the MEA Technetium-99m market is expected to experience steady and sustained growth over the coming years.
Lantheus Holdings Inc; Curium; Jubilant Radiopharma; NorthStar Medical Radioisotopes, LLC; Sun RadioPharma (Sun Pharmaceutical Industries, Inc.); NTP Radioisotopes SOC Ltd; Cardinal Health Inc; Medi-Radiopharma; Eckert & Ziegler AG; and Isotope JSC are among the key Technetium-99m market players that are profiled in this market study.
The overall Technetium-99m market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the EMEA Technetium-99m market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the EMEA Technetium-99m market.